New Vaccine Study from Pfizer: Will Protect From Both Diseases
US pharmaceutical company Pfizer and German biotechnology company BioNTech have started working on a mixed vaccine targeting the Covid-19 and flu epidemic.
US pharmaceutical company Pfizer and German biotechnology company BioNTech have started developing a vaccine that targets both Covid-19 and the flu epidemic.
It was informed that the vaccine, which was developed as a single dose, was studied as a combination of mRNA Covid-19 vaccine, flu vaccine and Omicron reminder doses.
The study, supported by the German biotechnology company BioNTech, aims to evaluate the safety, tolerability and ability of the combination vaccine to elicit an immune response.
For the study to be conducted with 180 volunteers aged 18-64 in the USA, a dose was administered to the first volunteer.
